The Radboud Biobank has added one new sub-biobank to the collection: HEMLYM.
The Hematology-Lymphoma Biobank plans to collect blood, saliva, serum and cell-free DNA from every lymphoma patient, in addition to the residual material available from the Pathology department (tumor tissue), the Hematology department and the Laboratory of Hematology (bone marrow, peripheral blood and tumor tissue). In recent years, much progress has been made in the knowledge surrounding the processes involved in the development and progression of lymph node cancer and the response to therapy. The aim and ambition of HEMLYM is to improve the diagnosis and treatment of patients with lymphoma.
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
Growth Fund invests in Health-RI proposal for health data infrastructure10 May 2021
The Dutch Government has decided to honor Health-RI's proposal for a national health data infrastructure.read more